Genetic modulation of the pathway linking PLK1 to APC/C activation curtailed the proliferation of mutant KRAS G12D-expressing cancer cells, while ATP-competitive PLK1 inhibitors suppressed their growth as xenografts. The gene discussed is KRAS; the disease is cancer.